Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin
GYH Lip, A Keshishian, S Kamble… - Thrombosis and …, 2016 - thieme-connect.com
In addition to warfarin, there are four non-vitamin K antagonist oral anticoagulants (NOACs)
available for stroke prevention in non valvular atrial fibrillation (NVAF). There are limited …
available for stroke prevention in non valvular atrial fibrillation (NVAF). There are limited …
Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the …
GYH Lip, X Pan, S Kamble, H Kawabata… - … journal of clinical …, 2016 - Wiley Online Library
Background Limited data are available about the real‐world safety of non‐vitamin K
antagonist oral anticoagulants (NOAC s). Objectives To compare the major bleeding risk …
antagonist oral anticoagulants (NOAC s). Objectives To compare the major bleeding risk …
Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
PG Tepper, J Mardekian, C Masseria, H Phatak… - PloS one, 2018 - journals.plos.org
Limited real-world data are available regarding the comparative safety of non-vitamin K
antagonist oral anticoagulants (NOACs). The objective of this retrospective claims …
antagonist oral anticoagulants (NOACs). The objective of this retrospective claims …
Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation
G Adeboyeje, G Sylwestrzak, JJ Barron, J White… - Journal of managed …, 2017 - jmcp.org
BACKGROUND: The use of non-vitamin K oral anticoagulants (NOACs) has increased
steadily following marketing approval; however, their relative safety in nonvalvular atrial …
steadily following marketing approval; however, their relative safety in nonvalvular atrial …
Major bleeding complications and persistence with oral anticoagulation in non‐valvular atrial fibrillation: contemporary findings in real‐life Danish patients
M Lamberts, L Staerk, JB Olesen… - Journal of the …, 2017 - Am Heart Assoc
Background The nonvitamin K antagonist oral anticoagulants have recently become
available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on …
available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on …
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban …
A Amin, A Keshishian, J Trocio, O Dina… - … medical research and …, 2017 - Taylor & Francis
Objective: To compare the risk and cost of stroke/systemic embolism (SE) and major
bleeding between each direct oral anticoagulant (DOAC) and warfarin among non-valvular …
bleeding between each direct oral anticoagulant (DOAC) and warfarin among non-valvular …
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants
S Halvorsen, W Ghanima, I Fride Tvete… - European Heart …, 2017 - academic.oup.com
Aims We aimed to evaluate bleeding risk in clinical practice in patients with atrial fibrillation
(AF) being prescribed dabigatran, rivaroxaban, or apixaban compared with warfarin …
(AF) being prescribed dabigatran, rivaroxaban, or apixaban compared with warfarin …
Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide …
L Staerk, EL Fosbøl, GYH Lip, M Lamberts… - European heart …, 2017 - academic.oup.com
Background Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) are widely used
as stroke prophylaxis in non-valvular atrial fibrillation (AF), but comparative data are sparse …
as stroke prophylaxis in non-valvular atrial fibrillation (AF), but comparative data are sparse …
Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation
PA Noseworthy, X Yao, NS Abraham… - Chest, 2016 - Elsevier
Background The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) has
been a major advance for stroke prevention in atrial fibrillation (AF). Patients and clinicians …
been a major advance for stroke prevention in atrial fibrillation (AF). Patients and clinicians …
Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study
SH Hohnloser, E Basic, M Nabauer - Clinical Research in Cardiology, 2017 - Springer
Background Non-vitamin K antagonist oral anticoagulants (NOACs) are at least as effective
and safe as vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF). All …
and safe as vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF). All …